Significant Ownership of GILEAD SCIENCES, INC.

Signature - Title: /s/ Andrew D. Dickinson - Andrew D. Dickinson, Executive Vice President and Chief Financial Officer
Location: Foster City, CA
Summary: This page shows a list of all the recent SCHEDULE 13D/G filings made by GILEAD SCIENCES, INC..

Notify me when GILEAD SCIENCES, INC. files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of GILEAD SCIENCES, INC.

Sym	Company	Class	Ownership	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
GLPG	Galapagos NV	Ordinary Shares, no par value	29.9%	$555,786,955		20,981,010		Gilead Sciences, Inc.	07 Jan 2025
ASMB	ASSEMBLY BIOSCIENCES, INC.	Common Stock, par value $0.001	29%			4,505,391	+1%	GILEAD SCIENCES, INC.	08 Aug 2025
RCUS	Arcus Biosciences, Inc.	Common Stock, par value $0.0001	25.6%	$427,376,736		31,424,760	0%	GILEAD SCIENCES, INC.	03 Nov 2025
XLO	Xilio Therapeutics, Inc.	Common Stock, par value $0.0001 per share	19.9%	$7,748,179	$1,101,199	10,613,944	+16.6%	GILEAD SCIENCES, INC.	30 Jun 2025
KLRS	Kalaris Therapeutics, Inc.	Common Stock, $0.0001 per value	3.9%	$4,715,740		723,273		GILEAD SCIENCES, INC.	18 Mar 2025
IKNA	Ikena Oncology, Inc.	Common Stock	3.6%	$1,612,591		1,521,312		GILEAD SCIENCES INC	31 Dec 2024

Schedules 13D/G Reported by GILEAD SCIENCES, INC.:

Sym	Target	Class	Ownership	Change	Current Shares	Change	Value	Reporting name	Form	Report Period	Filing Date

* An asterisk sign (*) next to the price indicates that the price is likely invalid.